GlassScriptPhysician profile
Shane Mark Watts
NPI 1285385005
$12,674.62
in general payments reported to CMS, 2019-2025
24 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,815 · 2023: $3,665 · 2024: $4,109 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $51.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,807.97 |
| Education | $51.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,935.03 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,756.50 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $1,188.34 | 2022-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $1,109.62 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $927.04 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $869.74 | 2022-2025 | Rexulti |
| Neos Therapeutics, LP | $694.01 | 2023-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $554.81 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $542.54 | 2022-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $517.22 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $493.48 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $383.21 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $328.55 | 2024-2025 | Hetlioz, Fanapt |
| Corium, LLC | $302.33 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $278.01 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $218.45 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $194.74 | 2023-2025 | Spravato, Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $185.04 | 2023-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $99.30 | 2023-2025 | Loreev Xr |
| Alfasigma USA, INC. | $39.41 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.69 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $14.00 | 2024 | |
| Abbott Laboratories | $13.63 | 2025 | Freestyle Libre 3 |
| Neuronetics, INC. | $12.93 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.